HCPCS Level II C9069: Injection, belantamab mafodontin-blmf, 0.5 mg - OpenPayer

Summary & Overview

HCPCS Level II C9069: Injection, belantamab mafodontin-blmf, 0.5 mg

HCPCS Level II code C9069 designates the injectable oncology agent belantamab mafodontin-blmf in 0.5 mg units. As a drug-specific HCPCS code, C9069 enables standardized billing and tracking for administration of this antibody-drug conjugate in outpatient infusion settings, supporting reimbursement workflows and utilization monitoring at a national level. Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and the clinical context for use. The publication outlines payer coverage considerations and common billing modifiers, summarizes where this HCPCS code fits within oncology service lines, and highlights implications for claims processing and coding accuracy. This resource is intended for billing professionals, revenue cycle managers, and clinical administrators seeking a clear, national-level overview of HCPCS Level II code C9069, including operational and policy factors that affect billing and documentation. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareC9069HCPCS Level IIbelantamab mafodontinoncologyinfusioninjectable drugdrug administrationoutpatient clinic

Billing Code Overview

HCPCS Level II code C9069 represents Injection, belantamab mafodontin-blmf, 0.5 mg. This code is used to report administration of the specified antibody-drug conjugate formulation by unit of 0.5 mg. The service type is an injectable oncology drug administration, and the typical site of service is an infusion center or outpatient oncology clinic.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with relapsed or refractory multiple myeloma who has exhausted standard lines of therapy and is being considered for targeted antibody–drug conjugate therapy. The patient presents to an outpatient oncology infusion center for administration of C9069 (injection, belantamab mafodotin-blmf, 0.5 mg). Pre-infusion evaluation includes review of prior therapies, ocular exam (due to keratopathy risk), laboratory tests including complete blood count, basic metabolic panel, and assessment of infusion reaction risk. On the day of service the oncology nurse verifies informed consent, confirms baseline corneal findings with ophthalmology or certified corneal assessment, establishes IV access, and administers pre-medications as per institutional protocol. The medication is prepared by pharmacy in a sterile compounding area and delivered to the infusion suite. During infusion, vital signs are monitored frequently and the patient is observed for infusion-related reactions, ocular symptoms, and hematologic toxicity. Post-infusion, the patient receives discharge instructions including scheduled ophthalmology follow-up, symptom reporting guidance, and documentation of the administered dose using C9069 with any applicable modifier(s). Typical site of service is an outpatient hospital infusion center or freestanding infusion center; some patients may receive therapy in an ambulatory clinic owned by a cancer center. Billing is generated for the drug vial-based HCPCS Level II code C9069 and for associated CPT services for infusion administration, evaluation and management, and ocular monitoring as clinically appropriate.

Coding Specifications

Modifier	Description

HCPCS C9449: Blinatumomab Injection, 1 mcg

HCPCS-LEVEL-II-C9742-FLEXIBLE-LARYNGOSCOPY-INJECTION-VOCAL-CORD

HCPCS Level II C9742: Flexible Fiberoptic Laryngoscopy with Vocal Cord Injection

HCPCS-C9071-VILTOLARSEN-INJECTION-10MG

HCPCS C9071: Injection, Viltolarsen 10 mg

HCPCS-C9307-LINVOSELTAMAB-INJECTION-1MG

HCPCS C9307: Linvoseltamab-gcpt Injection, 1 mg

HCPCS-C9453-NIVOLUMAB-INJECTION-1MG

HCPCS C9453: Injection, nivolumab, 1 mg

HCPCS-C1766-INTRACARDIAC-ELECTROPHYSIOLOGY-SHEATH-GUIDING-STEERABLE

HCPCS C1766: Intracardiac Electrophysiology Steerable Guiding Sheath

HCPCS-C9758-INTERATRIAL-SHUNT-INVESTIGATIONAL-IMPLANTATION-BLINDED

HCPCS C9758: Blinded Interatrial Shunt Implantation for NYHA III/IV Heart Failure

HCPCS-C2622-PENILE-NON-INFLATABLE-PROSTHESIS

HCPCS C2622: Prosthesis, Penile, Non-Inflatable

HCPCS-C1827-IMPLANTABLE-NON-RECHARGEABLE-NEUROSTIMULATOR-GENERATOR

HCPCS C1827: Implantable Non-Rechargeable Neurostimulator Generator

HCPCS-C7556-BRONCHOSCOPY-EBUS-BALVEOLAR-LAVAGE-PERIPHERAL-LESION

HCPCS C7556: Bronchoscopy with EBUS and Bronchoalveolar Lavage

Showing 1–10 of 603

Taxonomy Code	Specialty	Notes
`207RR0500X`	Hematology/Oncology	Medical oncologists and hematologist-oncologists prescribe and oversee belantamab mafodotin-blmf therapy.
`363L00000X`	Medical Oncology	Oncology specialists who manage systemic anti-cancer infusion therapy in outpatient settings.
`207X00000X`	Oncology	General oncology practice billing and oversight of infusion treatment plans.
`207W00000X`	Ophthalmology	Ophthalmologists perform baseline and surveillance corneal exams due to ocular toxicity risk.
`364S00000X`	Hematology	Hematologists involved when blood-count management and bone marrow-related complications occur.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C90.00`	Multiple myeloma not having achieved remission	Primary malignant plasma cell disorder commonly treated with novel antineoplastic agents including belantamab mafodotin-blmf in relapsed/refractory disease.
`C90.01`	Multiple myeloma in remission	May be used when documenting maintenance or post-treatment status following therapy.
`C90.02`	Multiple myeloma with relapse	Indicates relapse status for which belantamab mafodotin-blmf may be indicated.
`D47.Z2`	Monoclonal gammopathy of undetermined significance (MGUS)	Related plasma cell disorders that require differentiation from active multiple myeloma during treatment planning.
`D61.9`	Aplastic anemia, unspecified	Hematologic complications such as severe cytopenias can impact dosing and monitoring for antineoplastic therapy and may be relevant to pre-infusion evaluation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion; each additional hour (List separately in addition to primary)	Used when the infusion time for belantamab mafodotin-blmf extends beyond the time captured by the primary infusion CPT (paired with a primary infusion code such as `96415` when applicable).
`96415`	Chemotherapy administration, intravenous infusion; for therapy requiring highly complex, constant supervision	Used when the infusion requires prolonged monitoring and complex care; documents administration services for antineoplastic agents.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic	Applicable when an alternative route of administration is used, though belantamab mafodotin-blmf is typically IV.
`99212`	Office or other outpatient visit for the evaluation and management of an established patient, low complexity	Used for the clinic visit associated with assessment before or after infusion when appropriate.
`99070`	Supplies and materials (except spectacles), non-covered items	Used for clinic-supplied supplies associated with infusion that are not otherwise billed (e.g., special eye-drops if not separately reimbursed).
`CPT 92012`	Ophthalmological services: intermediate ophthalmological examination and management, established patient	Used for ophthalmology surveillance visits to evaluate corneal toxicity; documents ocular assessment in the treatment workflow.

`22`	Increased procedural services	Use when administration required substantially greater resource use (rare for standard infusion; documented justification required).
`23`	Unusual anesthesia	Use only if unusual anesthesia unrelated to the procedure is required (unlikely for outpatient infusion).
`52`	Reduced services	Use when the full drug dose or service was partially reduced or not completed.
`53`	Discontinued procedure	Use when infusion is started but discontinued due to patient condition or reaction.
`54`	Surgical care only	Not typically used for drug infusion; may apply if separate surgical procedure performed by another provider.
`55`	Postoperative management only	Not typically applicable to infusion services.
`56`	Preoperative management only	Not typically applicable to infusion services.
`62`	Two surgeons	Use when two qualified providers share performance of a related invasive procedure (rare for infusion).
`AS`	Left heart catheterization	Not applicable; included in list but generally unused for infusion therapy.
`QK`	Medical direction of two, three, or four assistants	Use when the billing physician medically directs assistants relevant to a concurrent procedure.

OpenPayer